Abstract
The role of transforming growth factor β receptor type 1 (TGFBR1) polymorphisms, particularly a coding CGC insertion (rs11466445, TGFBR1*6A/9A) in exon 1, has been extensively investigated in regard to colorectal cancer (CRC) risk. These investigations have generated conflicting results. More recently, allele-specific expression (ASE) of TGFBR1 mRNA has been suggested as predisposing to CRC, with a relative risk of nearly 10-fold and a population attributable risk of ∼10%. Owing to the potential importance of TGFBR1 variants in CRC, we performed a comprehensive examination of tagging SNPs at and around the gene in 3,101 CRC cases and 3,334 controls of northern European ancestry. To test whether rare or subpolymorphic TGFBR1 variants were associated with CRC risk, we sequenced the gene's exons in a subset of patients. We also evaluated TGFBR1 ASE in a panel of CRC cases and controls. Overall, we found no association between TGFBR1 polymorphisms and CRC risk. The rare variant screen did not identify any changes of potentially pathogenic effects. No evidence of greater ASE in cases than controls was detected, and no haplotype around TGFBR1 could account for the ASE reported in other studies. We conclude that neither genetic variation nor ASE at TGFBR1 is likely to be a major CRC risk factor.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 7858-7862 |
| Number of pages | 5 |
| Journal | Proceedings of the National Academy of Sciences of the United States of America |
| Volume | 107 |
| Issue number | 17 |
| DOIs | |
| State | Published - Apr 27 2010 |
| Externally published | Yes |
Fingerprint
Keywords
- Candidate gene
- Genetic susceptibility
- Low penetrance
- TGF signaling
- Transforming growth factor β receptor type 1 *6A/9A
ASJC Scopus subject areas
- General
Cite this
Comprehensive assessment of variation at the transforming growth factor β type 1 receptor locus and colorectal cancer predisposition. / Carvajal-Carmona, Luis; Churchman, Mike; Bonilla, Carolina; Walther, Axel; Lefèvre, Jeremie H.; Kerr, David; Dunlop, Malcolm; Houlston, Richard; Bodmer, Walter F.; Tomlinson, Ian.
In: Proceedings of the National Academy of Sciences of the United States of America, Vol. 107, No. 17, 27.04.2010, p. 7858-7862.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Comprehensive assessment of variation at the transforming growth factor β type 1 receptor locus and colorectal cancer predisposition
AU - Carvajal-Carmona, Luis
AU - Churchman, Mike
AU - Bonilla, Carolina
AU - Walther, Axel
AU - Lefèvre, Jeremie H.
AU - Kerr, David
AU - Dunlop, Malcolm
AU - Houlston, Richard
AU - Bodmer, Walter F.
AU - Tomlinson, Ian
PY - 2010/4/27
Y1 - 2010/4/27
N2 - The role of transforming growth factor β receptor type 1 (TGFBR1) polymorphisms, particularly a coding CGC insertion (rs11466445, TGFBR1*6A/9A) in exon 1, has been extensively investigated in regard to colorectal cancer (CRC) risk. These investigations have generated conflicting results. More recently, allele-specific expression (ASE) of TGFBR1 mRNA has been suggested as predisposing to CRC, with a relative risk of nearly 10-fold and a population attributable risk of ∼10%. Owing to the potential importance of TGFBR1 variants in CRC, we performed a comprehensive examination of tagging SNPs at and around the gene in 3,101 CRC cases and 3,334 controls of northern European ancestry. To test whether rare or subpolymorphic TGFBR1 variants were associated with CRC risk, we sequenced the gene's exons in a subset of patients. We also evaluated TGFBR1 ASE in a panel of CRC cases and controls. Overall, we found no association between TGFBR1 polymorphisms and CRC risk. The rare variant screen did not identify any changes of potentially pathogenic effects. No evidence of greater ASE in cases than controls was detected, and no haplotype around TGFBR1 could account for the ASE reported in other studies. We conclude that neither genetic variation nor ASE at TGFBR1 is likely to be a major CRC risk factor.
AB - The role of transforming growth factor β receptor type 1 (TGFBR1) polymorphisms, particularly a coding CGC insertion (rs11466445, TGFBR1*6A/9A) in exon 1, has been extensively investigated in regard to colorectal cancer (CRC) risk. These investigations have generated conflicting results. More recently, allele-specific expression (ASE) of TGFBR1 mRNA has been suggested as predisposing to CRC, with a relative risk of nearly 10-fold and a population attributable risk of ∼10%. Owing to the potential importance of TGFBR1 variants in CRC, we performed a comprehensive examination of tagging SNPs at and around the gene in 3,101 CRC cases and 3,334 controls of northern European ancestry. To test whether rare or subpolymorphic TGFBR1 variants were associated with CRC risk, we sequenced the gene's exons in a subset of patients. We also evaluated TGFBR1 ASE in a panel of CRC cases and controls. Overall, we found no association between TGFBR1 polymorphisms and CRC risk. The rare variant screen did not identify any changes of potentially pathogenic effects. No evidence of greater ASE in cases than controls was detected, and no haplotype around TGFBR1 could account for the ASE reported in other studies. We conclude that neither genetic variation nor ASE at TGFBR1 is likely to be a major CRC risk factor.
KW - Candidate gene
KW - Genetic susceptibility
KW - Low penetrance
KW - TGF signaling
KW - Transforming growth factor β receptor type 1 6A/9A
UR - http://www.scopus.com/inward/record.url?scp=77952367661&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77952367661&partnerID=8YFLogxK
U2 - 10.1073/pnas.1002816107
DO - 10.1073/pnas.1002816107
M3 - Article
VL - 107
SP - 7858
EP - 7862
JO - Proceedings of the National Academy of Sciences of the United States of America
JF - Proceedings of the National Academy of Sciences of the United States of America
SN - 0027-8424
IS - 17
ER -